Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2021; 53(07): 435-443
DOI: 10.1055/a-1525-2070

Endocrine Care

Predicting the Course of Graves’ Orbitopathy Using Serially Measured TSH-Receptor Autoantibodies by Automated Binding Immunoassays and the Functional Bioassay

Mareile Stöhr

¹Department of Ophthalmology, University Hospital Essen, Essen, Germany

,

Michael Oeverhaus

¹Department of Ophthalmology, University Hospital Essen, Essen, Germany

,

Simon D. Lytton

²SeraDiaLogistics, Munich, Germany

,

Mareike Horstmann

¹Department of Ophthalmology, University Hospital Essen, Essen, Germany

,

Denise Zwanziger

³Department of Endocrinology, Diabetes and Metabolism, Division of Laboratory Research, University of Duisburg-Essen, Essen, Germany

,

Lars Möller

³Department of Endocrinology, Diabetes and Metabolism, Division of Laboratory Research, University of Duisburg-Essen, Essen, Germany

,

Achim Stark

⁴Practice for General Medicine, Essen, Germany

,

Dagmar Führer-Sakel

³Department of Endocrinology, Diabetes and Metabolism, Division of Laboratory Research, University of Duisburg-Essen, Essen, Germany

,

Nikolaos Bechrakis

¹Department of Ophthalmology, University Hospital Essen, Essen, Germany

,

Utta Berchner-Pfannschmidt

³Department of Endocrinology, Diabetes and Metabolism, Division of Laboratory Research, University of Duisburg-Essen, Essen, Germany

,

J. Paul Banga

⁵Emeritus, King’s College London, London, UK

,

Svenja Philipp‡

³Department of Endocrinology, Diabetes and Metabolism, Division of Laboratory Research, University of Duisburg-Essen, Essen, Germany

,

Anja Eckstein‡

¹Department of Ophthalmology, University Hospital Essen, Essen, Germany

› Author Affiliations

Abstract

The aim of the study was to investigate the use of serial measurements of TSH-receptor autoantibodies (TRAb) with the newest available assay technology to predict the course of Graves’ Orbitopathy (GO) during the first 24 months from disease onset. Serial serum samples from patients with GO (103 mild/135 severe) were collected between 2007 and 2017 and retrospectively analyzed. The course of GO were classified into mild/severe 12 months after manifestation (severe: NOSPECS≥5; mild<5). TRAb were measured with automated binding immunoassays (IU/l): TRAb Elecsys (Cobas, Roche), TRAb bridge assay (IMMULITE, Siemens), and a cell-based bioassay (percent of specimen to reference ratio - SRR%) (Thyretain, Quidel). Variable cut off levels of measured TRAb were calculated at specificity of 90% from receiver operator curve (ROC) analysis for several timepoints during the course of GO. To select one: 5–8 months after first GO symptoms, which is the timepoint for usual referals for treatment mild course could be predicted at cut offs of 1.5 IU/l (Elecsys), 0.8 IU/l (Immulite) and 402% SRR (Thyretain) and the risc of severe course has to be anticipated if TRAb are above 11.6 IU/l (Elecsys), 6.5 IU/l (Thyretain), and 714% SRR (Thyretain). The Thyretain bioassay showed the highest diagnostic sensitivity (using the commercial cut off’s) over the entire follow up period. TRAb measurements during the 24-month follow up of GO provide added value to the GO clinical activity and severity scores and should be used especially in the event of an unclear decision-taking situation with regard to therapy.

Key words

Key words

Graves’ orbitopathy - TSH-receptor antibodies - functional antibodies - binding assays - bioassays

References
1 Ehlers M, Schott M, Allelein S. Graves’ disease in clinical perspective. Front Biosci (Landmark Ed) 2019; 24: 35-47
2 Bahn RS. Current Insights into the Pathogenesis of Graves’ Ophthalmopathy. Horm Metab Res 2015; 47: 773-778
3 Krieger CC, Neumann S, Gershengorn MC. TSH/IGF1 receptor crosstalk: Mechanism and clinical implications. Pharmacol Ther 2020; 107502
4 Gortz GE, Moshkelgosha S, Jesenek C. et al. Pathogenic Phenotype of Adipogenesis and Hyaluronan in Orbital Fibroblasts From Female Graves’ Orbitopathy Mouse Model. Endocrinology 2016; 157: 3771-3778
5 Berchner-Pfannschmidt U, Moshkelgosha S, Diaz-Cano S. et al. Comparative assessment of female mouse model of Graves’ orbitopathy under different environments, accompanied by pro-inflammatory cytokine and T cell responses to thyrotropin hormone receptor antigen. Endocrinology 2016; 157: 1673-1682
6 Moshkelgosha S, So PW, Deasy N. et al. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves’ orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation. Endocrinology 2013; 154: 3008-3015
7 Johnson KT, Wiesweg B, Schott M. et al. Examination of orbital tissues in murine models of Graves’ disease reveals expression of UCP-1 and the TSHR in retrobulbar adipose tissues. Horm Metab Res 2013; 45: 401-407
8 Uddin JM, Rubinstein T, Hamed-Azzam S. Phenotypes of Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg 2018; 34: S28-S33
9 Ponto KA, Merkesdal S, Hommel G. et al. Public health relevance of Graves’ orbitopathy. J Clin Endocrinol Metab 2013; 98: 145-152
10 Bartalena L, Baldeschi L, Boboridis K. et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J 2016; 5: 9-26
11 Bartalena L, Baldeschi L, Dickinson AJ. et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid 2008; 18: 333-346
12 Bartalena L, Baldeschi L, Dickinson A. et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008; 158: 273-285
13 Seo S, Sanchez Robledo M. Usefulness of TSH receptor antibodies as biomarkers for Graves’ ophthalmopathy: a systematic review. J Endocrinol Invest 2018; 41: 1457-1468
14 Eckstein A, Esser J, Mann K. et al. Clinical value of TSH receptor antibodies measurement in patients with Graves’ orbitopathy. Pediatr Endocrinol Rev 2010; 7: 198-203
15 Lytton SD, Schluter A, Banga PJ. Functional diagnostics for thyrotropin hormone receptor autoantibodies: bioassays prevail over binding assays. Front Biosci (Landmark Ed) 2018; 23: 2028-2043
16 Ehlers M, Allelein S, Schott M. TSH-receptor autoantibodies: pathophysiology, assay methods, and clinical applications. Minerva Endocrinol 2018; 43: 323-332
17 Eckstein AK, Plicht M, Lax H. et al. Clinical results of anti-inflammatory therapy in Graves’ ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf) 2004; 61: 612-618
18 Autilio C, Morelli R, Locantore P. et al. Stimulating TSH receptor autoantibodies immunoassay: analytical evaluation and clinical performance in Graves’ disease. Ann Clin Biochem 2018; 55: 172-177
19 Smith BR, Bolton J, Young S. et al. A new assay for thyrotropin receptor autoantibodies. Thyroid 2004; 14: 830-835
20 Hermsen D, Broecker-Preuss M, Casati M. et al. Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies. Clin Chim Acta 2009; 401: 84-89
21 Schott M, Hermsen D, Broecker-Preuss M. et al. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves’ disease (GD): An international multicentre trial. Clin Endocrinol (Oxf) 2009; 71: 566-573
22 Frank CU, Braeth S, Dietrich JW. et al. Bridge Technology with TSH Receptor Chimera for Sensitive Direct Detection of TSH Receptor Antibodies Causing Graves’ Disease: Analytical and Clinical Evaluation. Horm Metab Res 2015; 47: 880-888
23 Allelein S, Ehlers M, Goretzki S. et al. Clinical Evaluation of the First Automated Assay for the Detection of Stimulating TSH Receptor Autoantibodies. Horm Metab Res 2016; 48: 795-801
24 Tozzoli R, D’Aurizio F, Villalta D. et al. Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves’ disease. Clin Chem Lab Med 2017; 55: 58-64
25 Lytton S, Li Y, Olivo P. et al. Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulin. Clin Exp Immunol 2010; 162: 438-446
26 Laurberg P, Wallin G, Tallstedt L. et al. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: A 5-year prospective randomized study. Eur J Endocrinol 2008; 158: 69-75
27 Andrade VA, Gross JL, Maia AL. Serum thyrotropin-receptor autoantibodies levels after I therapy in Graves’ patients: effect of pretreatment with methimazole evaluated by a prospective, randomized study. Eur J Endocrinol 2004; 151: 467-474
28 Eckstein AK, Lax H, Losch C. et al. Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol (Oxf) 2007; 67: 607-612
29 Meyer Zu Horste M, Pateronis K, Walz MK. et al. The Effect of Early Thyroidectomy on the Course of Active Graves’ Orbitopathy (GO): A Retrospective Case Study. Horm Metab Res 2016; 48: 433-439
30 Jang SY, Shin DY, Lee EJ. et al. Relevance of TSH-receptor antibody levels in predicting disease course in Graves’ orbitopathy: Comparison of the third-generation TBII assay and Mc4-TSI bioassay. Eye (Lond) 2013; 27: 964-971
31 Eckstein AK, Plicht M, Lax H. et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006; 91: 3464-3470
32 Costagliola S, Morgenthaler NG, Hoermann R. et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves’ disease. J Clin Endocrinol Metab 1999; 84: 9097
33 Lantz M, Planck T, Asman P. et al. Increased TRAb and/or low anti-TPO titers at diagnosis of graves’ disease are associated with an increased risk of developing ophthalmopathy after onset. Exp Clin Endocrinol Diabetes 2014; 122: 113-117
34 Takakura A, Kirkeby K, Earle K. et al. Predicting the Development of Orbitopathy in Graves Thyroidopathy Patients: The Potential Role of TSI Testing. Ophthalmic Plast Reconstr Surg 2015; 31: 369-372
35 Jang SY, Shin DY, Lee EJ. et al. Clinical characteristics of Graves’ orbitopathy in patients showing discrepancy between levels from TBII assays and TSI bioassay. Clin Endocrinol (Oxf) 2014; 80: 591-597
36 Hiromatsu Y, Eguchi H, Matsuo Y. et al. Role of a new bioassay for thyroid-stimulating antibodies (aequorin TSAb) in Graves’ ophthalmopathy. Endocr J 2020; 67: 347-352
37 Roos JCP, Paulpandian V, Murthy R. Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: The impact of smoking, immunosuppression, radio-iodine, and thyroidectomy. Eye (Lond) 2019; 33: 212-217
38 Lytton SD, Ponto KA, Kanitz M. et al. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab 2010; 95: 2123-2131
39 Woo YJ, Jang SY, Lim TH. et al. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves’ Orbitopathy. Korean J Ophthalmol 2015; 29: 213219
40 Stöhr M, Oeverhaus M, Lytton SD. et al. Predicting the Relapse of Hyperthyroidism in Treated Graves’ Disease with Orbitopathy by Serial Measurements of TSH-Receptor Autoantibodies. Horm Metab Res 2021; 53: 235-244
41 Bartalena L, Veronesi G, Krassas GE. et al. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy?. J Endocrinol Invest 2017; 40: 547-553
42 Marcocci C, Kahaly GJ, Krassas GE. et al. Selenium and the course of mild Graves’ orbitopathy. N Eng J Med 2011; 364: 1920-1931
43 Hermsen D, Liu C, Domberg J. et al. Comparison of a solid phase human- versus porcine- thyrotropin receptor-based immunoassay for the measurement of thyrotropin receptor antibodies in patients with thyroid diseases. Exp Clin Endocrinol Diabetes 2008; 116: S59-S63
44 Kashiwai T, Tada H, Asahi K. et al. Significance of thyroid stimulating antibody and long term follow up in patients with euthyroid Graves’ disease. Endocr J 1995; 42: 405-412
45 Kahaly GJ, Diana T, Glang J. et al. Thyroid Stimulating Antibodies Are Highly Prevalent in Hashimoto’s Thyroiditis and Associated Orbitopathy. J Clin Endocrinol Metab 2016; 101: 1998-2004
46 Khoo DH, Ho SC, Seah LL. et al. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves’ disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid 1999; 9: 1175-1180